

## What is the focus of Luminous Mind Inc.?

### PSYCHIATRIC AND PSYCHEDELIC TREATMENTS – PATENTS / IP

We are dedicated to developing superior and differentiated treatments for psychiatric illness, including depression, pain, anxiety, PTSD and addiction, through a rigorous therapeutic discovery and development process. Sources of compounds include the repurposing of existing, abandoned, and developmental compounds for new indications, as well as plants with known Central Nervous System (CNS) active compounds.

## What is the strategy for Luminous Mind Inc.?

### DEVELOPMENT STRATEGY

To minimize risk, and maximize societal impact, the larger opportunity lies in building a robust and diverse product pipeline of high-value potential drug candidates to treat psychiatric illnesses. We take what is known but understudied from ethnobotanists and make judicious selections of botanical/fungal candidates from global bioresources. We plan to develop patented analogs of psychedelic compounds that are engineered to eliminate hallucinogenic properties but retain brain plasticity, anti-inflammatory, and immunomodulatory activities.

### Pipeline

Compound	Indication	Discovery	Preclinical	Phase 1a/1b	Phase 2	Phase 3	Expected regulatory approval/partnering
Repurposed Drugs (2)*	Anxiety, Depression, other	2022					Estimated approval 2024, partner post Phase 2
5-MeO-DMT	Depression, other	2022					Partner after Phase 2
Phytochemical NCE	TBD	2022					Partner after Phase 1
Mushroom Engineering	Anti-inflammatory	Nutraceutical 2023					Commercial partner

\* Non-US Marketed drugs for new indications


## What is unique about the Luminous Mind Inc. team?

### TEAM

Our multi-disciplinary team of "drug hunting scientists" with cumulative 100+ years of CNS drug experience has known each other for decades. More details on the next page.

## What differentiates Luminous Mind Inc. from others?

We are an IP centric company, establishing key academic partnerships. We drive valuation and build our pipeline by repurposing drugs with well understood safety profiles for new indications. We plan to develop patented New Chemical Entities (NCEs) based on known bioactives from plants that have been used by Shamans in traditional medicine. Additionally, we are implementing a mushroom gene editing initiative using groundbreaking CRISPR technology to develop patented nutraceuticals.




## PSYCHEDELIC RENAISSANCE

Psychedelic drugs and psychedelic-inspired molecules are being evaluated in a range of serious neuropsychiatric and neurodegenerative disorders. The prevalence of these conditions is growing, and the needs of significant populations are unmet or underserved by currently available treatments. Our Team plans to develop novel drugs to address these unmet needs.

### TEAM

#### 100+ YEARS OF CNS EXPERIENCE

Our multi-disciplinary team of ‘drug hunters’ has pioneered the research & development of therapeutics that have helped millions of people worldwide. Our team has known each other for decades and has reunited to help defeat brain diseases and will play an important role in the psychedelic renaissance.



### SCIENTIFIC AND MANAGEMENT TEAM INCLUDES

- **Louis Herlands, PhD** - Successful serial biotech and pharmaceutical entrepreneur
- **Dan Bradbary, MBA** – Specialist in implementation of management control systems
- **Marcie Glicksman, PhD** - Former Director of Harvard Neurodegeneration Drug Discovery Center
- **David Bleakman, PhD** - Former Chief Scientific Officer, Eli Lilly and Co.
- **David Borsook, MD, PhD** - Pioneer in brain systems biology using Imaging for CNS therapeutics
- **Richard Kosman, Sc.M.M.** – Technology transfer, business development, investment banker
- **Michael Petrone, MD, MPH** - Expert in clinical development and medical affairs
- **David Thaler, PhD** - Geneticist and expert on psychedelic risk reduction
- **Former Chair** of two academic Psychiatry Departments
- **Drore Eisen, MD** - Expert in inflammation, and dermatology
- **Former Head** of high throughput screening and assay development, Glaxo
- **Alan Jacobson, PhD, MBA** - Medicinal chemist
- **Former Chief Editor** of *Nature Genetics*

***Defeating CNS disorders that are among the most serious medical challenges facing humanity.***

*The Psychedelic Renaissance has opened opportunities for developing novel CNS therapeutics that will transform medicine.*